Jubilant Ingrevia zooms on acquiring 100% equity stake in Remidex Pharma
This acquisition will enable Jubilant Ingrevia to move forward in the value chain towards Premixes in Human Nutrition Space building upon its leadership position in Vitamins (Vitamin B3 & B4)
Jubilant Ingrevia is currently trading at Rs. 565.25, up by 21.60 points or 3.97% from its previous closing of Rs. 543.65 on the BSE.
The scrip opened at Rs. 554.55 and has touched a high and low of Rs. 571.35 and Rs. 551.05 respectively. So far 5169 shares were traded on the counter.
The BSE group 'A' stock of face value Rs. 1 has touched a 52 week high of Rs. 851.85 on 17-Jul-2025 and a 52 week low of Rs. 535.30 on 02-Mar-2026.
Last one week high and low of the scrip stood at Rs. 667.90 and Rs. 541.00 respectively. The current market cap of the company is Rs. 9063.89 crore.
The promoters holding in the company stood at 45.22%, while Institutions and Non-Institutions held 30.16% and 24.62% respectively.
Jubilant Ingrevia has acquired 100% equity stake in Remidex Pharma (Remidex) pursuant to the Share Purchase Agreement entered into with Remidex.
This acquisition will enable Jubilant Ingrevia to move forward in the value chain towards Premixes in Human Nutrition Space building upon its leadership position in Vitamins (Vitamin B3 & B4).
Jubilant Ingrevia, a global integrated Life Science products and Innovative Solutions provider serving, Pharmaceutical, Nutrition, Agrochemical, Consumer and Industrial customers.
